

DataMEDS Ai

NASDAQ: MEDS

(Strategic transaction framework: term sheet signed May 19, 2026; updated on July, 29, 2026
definitive agreements pending)

NASDAQ: MEDS (formerly WGRX)

*Delivering Healthcare's Future —
One Patient at a Time*

The healthcare-focused, AI-powered, blockchain-enabled, drone-delivered
pharmaceutical platform born from a landmark multi-party strategic transaction.

\$4B

Expected Approximate Post-Acquisition Asset Value

5

Strategic Partners

5

QOLPOM Patents Being Acquired

10.4%

Legacy Wellgistics Shareholder Ownership





Legal Disclaimer

Forward-Looking Statements

This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that reflect current views of the Company with respect to, among other things, operations and financial performance. Forward-looking statements may be identified by the use of words such as "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "potential", "predict", "project", "future", "will", "seek", "foreseeable" and similar terms and phrases in this presentation. Forward-looking statements contained in this presentation are based on the management's current expectations and are subject to changes in circumstances and other risks and uncertainties. The Company cannot assure you that future developments affecting the Company will be those that the Company has anticipated. Actual results may differ materially from these expectations due to changes in global, regional or local economic, business, competitive, market, regulatory and other factors, many of which are beyond the control of the Company. Any forward-looking statement made by the Company in this presentation speaks only as of the date of this presentation. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward looking statements. Forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, investments or other strategic transactions the Company may make. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

About Us



Founder-led (2017-2024):

Wellgistics, LLC established to empower independent pharmacies



2024 Integration:

Merged into Wellgistics Health and completed key acquisitions: Community Specialty Pharmacy and Alliance Pharma Solutions via WoodSage, including tech platforms DataMeds™ and EinsteinRx™



IPO on NASDAQ:

Listed under ticker WGRX on February 21, 2025



Proven scale:

\$600M+ in drug sales lifetime, operating nationwide with a proprietary tech stack



Fully integrated ecosystem:

Manufacturer > distribution > hub services
> pharmacy > patient



Mission-driven growth:

Proposed consolidation of Blockchain, drone and biometric IP w/DTC app-based outlet for healthcare; definitive agreements pending

PROBLEM FOR THE “5 Ps”

The Broken Healthcare Supply Chain

MARKET CHOKE POINT



Pharmaceutical Manufacturers

Value lost in PBM rebates, excessive distributor fees, lack of patient connection.



Pharmacies

Independents squeezed by PBMs through spread pricing and steering, margins collapsing.



Patients

Lack of coverage, prior authorizations, higher out-of-pocket costs, delays, and poor adherence.



Providers

Pharmacy spend rising 8-10% annually, trapped in opaque PBM contracts.



Payors

Payors receive fragmented information with insufficient data to make ethical cost-effective decisions, thus costs spiral

The Problem & Our Solution

Addressing a Broken System

Patients Face Rising Costs & Terrible Choices

THE PROBLEM

- 50M+ Americans struggle with medication non-adherence annually
- Last-mile pharmaceutical delivery remains inefficient, error-prone & expensive
- No secure, biometrically verified delivery standard exists today
- Fragmented health data siloed across incompatible systems
- Pharmacy staffing crises driving up dispensing costs
- Pharmaceuticals often come with side effects or no drugs are available for medical conditions



THE DataMeds AI SOLUTION

- Blockchain-enabled PharmacyChain™ for secure, transparent transaction records
- Drone-delivered pharmaceuticals with biometric identity verification at the door
- DataVault AI Health — data monetization, credentialing & tokenization of real-world health assets
- Integrated patient monitoring & remote care coordination (QOLPOM IP)
- Health Lives Here (HLH) consumer & NFL Alumni Health community platform
- Tollo Health acquisition brings natural products that mitigate side effects/help symptoms if no treatments exist

The Investment Thesis



First-Mover Platform

DataMeds AI is positioned as the only public company combining AI, blockchain, biometrics, and drone technology in a unified pharmaceutical delivery stack.



Multi-Party IP Assembly

Five strategic partners are engaged under signed term sheets and proposed agreements to contribute IP, health infrastructure, and capital — creating barriers to competition that no single company could replicate.



Path to \$4B Valuation

A fairness opinion is expected to memorialize a \$4B post-acquisition enterprise value, anchored by milestone-based preferred share conversion mechanics.



Capitalized to Execute

\$6.5M already invested in new DataMeds AI vision, with commitment of partners to help raise \$20M upon DataMeds preferred-to-common conversion by transaction parties to help validate valuation

Leveraging Corexa Health's Pharmacy Business

15%



Rising Prescription Costs Per Year

Patients are faced with rising medication costs – 10-15% -avg drug increase per year

Source: CMS, AHA, Drug Channels

95%



Lack of Access Due to Monopolies

95% of access to and pricing of U.S. Drugs are controlled by the Six Largest PBMs/Payers

Source: FTC, Market Watch

1 in 3



Adults Skip Prescribed Meds Due to High Costs

Insurers' lack of coverage force a third of patients to skip prescribed medications.

Source: KFF: Kaiser Family Foundation / CAP: Center for American Progress



PHARMACIES

Face pressure from major wholesalers and PBMs, who control drug pricing and often keep manufacturer rebates, increasing costs and shrinking pharmacy profits.



DRUG MANUFACTURERS

Are stuck in PBMs' costly rebate programs, as well as regulatory mandates, compliance penalties, and delayed payments—with limited visibility into patient outcomes.



EMPLOYERS / HEALTHCARE PAYORS

Trapped by PBMs — Face annual price increases which they cannot understand, & which impacts the quality of coverage they provide to their members.



HEALTHCARE PROVIDERS


Operate blind—with limited visibility into drug costs, coverage, or fulfillment status, causing treatment delays and patient non-adherence.

The Wellgistics Health Solution

OUR THREE-PART ECOSYSTEM



- Serialization of drug distribution from manufacturer to patient creates opportunity to vertically integrate pharma supply chain
- Pharmacy subsidiaries renamed Corexa Pharmacy & Corexa Hub under new Corexa Health division — basis for integration of PharmacyChain™
- PharmacyChain™ blockchain-enabled smart contracts platform protected by DataVault AI license has necessary EHR data to build Healthcare-as-a-Service platform
- Integration of EinsteinRx™ into HaaSChain to engage provider and patients with more actionable reports to improve outcomes and lower costs



- App focused on compliance / coaching
- Health App of Health Apps
- Integrating
 - Telehealth
 - Labs
 - Health products
 - Pharmacy
 - Personalized messaging
- HOF Ambassadors: Woodson, Smith, Reed & Moon
 - 2M+ followers @HealthLivesHere
 - Fox Business' Claman Countdown (Aug 5) & HOF Enshrinement Week, Canton (Aug 7)



Health Lives Here – NFL Alumni Health Marketing Partnership

“Health Lives Here” App

Activation Timeline: NFL Draft (Pittsburgh, PA) → HOF Enshrinement Week (Canton, OH) → North Carolina Pilot Launch (September 2026) → National Pharmacy Launch (Q4 / 2026)

Improving outcomes through health engagement

Integrated Care Model

Health Lives Here & Corexa Pharmacy — A Fully Integrated Prescription-to-Dispensing Ecosystem

Health Lives Here App (Telehealth)



Corexa Pharmacy (Dispensing)

- Tollo Health's branded telehealth service powered by **MD Integration's white-label platform**
 - Patients consult licensed clinicians online and receive GLP-1 prescriptions digitally
 - Platform: async & live consults, prescription management, patient monitoring, HIPAA-compliant data infrastructure
 - Fast, scalable launch with low upfront infrastructure cost
- DataMeds AI's Pharmacy Division for dispensing drugs
 - Exclusive dispensing hub for GLP-1 prescriptions written through Health Lives Here app
 - Established pharmacy license, operational infrastructure, and patient relationships from KareRx accelerate launch
 - FORZET™ and companion products recommended at point of dispensing — driving cross-sell revenue

The Integrated Flywheel

Health Lives Here prescribes → Corexa Pharmacy dispenses → Tollo Health companion products recommended at dispensing →
Recurring revenue across telehealth, pharmacy & nutraceuticals

- Captures margin across the full care continuum
- Builds patient loyalty
- Generates proprietary real-world data to power future clinical studies and marketing

Transaction Overview

Strategic Transaction Framework — Term Sheet Signed May 19, 2026; Definitive Agreements Pending

DataMeds AI, Inc. (formerly Wellgistics Health, WGRX; now NASDAQ: MEDS)

Acquiring entity & public listing vehicle; pharmacy subsidiaries renamed Corexa Pharmacy, LLC and Corexa Hub, LLC under new Corexa Health, LLC division

EOS Technology Holdings

QOLPOM IP Portfolio 1 — drone delivery & biometric patents (proposed acquisition)

Scilex Holdings (SCLX)

QOLPOM IP Portfolio 2 — biometric data collection patents (proposed acquisition)

DataVault AI Inc. (DVLT)

PharmacyChain™ blockchain + DataVault AI Health license integration (license executed; integration ongoing)

HealthBridge Advisors (HBA)

Proposed controlling interest in Tollo Health / Health Lives Here (HLH) — non-binding letter of intent; definitive agreement not yet executed

Fortitude Advisors

Strategic executive advisory, Gerald Commissioning as Interim Co-CEO

IP & Technology Platform



Drone Delivery Layer (QOLPOM Patents from EOS, proposed)

- Remote Medication Delivery Systems (Patent 14/979,742)
- Remote User Monitoring System (Patent 14/979,889)
- System & Method for Providing Medication to a User (Patent 17/089,200)



Biometric Verification Layer (QOLPOM Patents from Scilex, proposed)

- Biometric Data Collection combining Visual Data with Health Records (15/876,815)
- Method & Apparatus for Determining User Information (17/892,524)
- Secure, personalized pharmaceutical delivery confirmation



Blockchain & Data Layer (DataVault AI Health)


- PharmacyChain™ — blockchain-enabled pharmaceutical distribution
- Data monetization, credentialing & digital engagement
- Tokenization of real-world healthcare assets



Care Coordination Layer (Health Lives Here / HLH)

- Consumer health engagement via "Health Lives Here" platform
- NFL Alumni Health partnership for community reach
- Integrated care management & patient navigation

Milestone Roadmap to Value Creation



Key Events to Drive Value for Each Transaction Participant:

- EOS & SCLX: Regulatory clearance to test drone delivery in at least 1 US state
- DVLH: IBM partnership expanded with signed SOW for ≥1,000 hours of DVLH development
- HBA: Agreement executed with NFL Alumni Health, LLC for "Health Lives Here" marketing

Market Opportunity

\$560B

US Pharmacy Market

Total addressable market for prescription dispensing

\$7B+

Drone Delivery Market

Expected global healthcare drone delivery by 2030

\$40B+

Health Data Monetization

Global digital health data market opportunity

\$528B

Medication Non-Adherence

Annual US economic cost — DataMeds AI directly addresses

Expert Leaders in Growth Execution



Prashant Patel, RPh
President & Interim Co-CEO

Former co-Founder, Director, President and COO of TRxADE Health, Inc. Pioneered innovative technology for secondary distribution, reverse distribution, and logistics.



Gerald Commissiong
Interim Co- CEO

Mr. Commissiong is the CEO of Tollo Health, LLC, and the CBO at OS Therapies (NYSE American: OSTX) Mr. Commissiong has extensive experience in healthcare, biotechnology, life sciences and strategic advisory services, including leadership positions involving public and private companies, having raised over \$100 million for his companies.



Eric Sherb,
Chief Financial Officer

Founder and Owner of EMS Consulting Services, with previous experiences at PwC, RBSM LLP, and CFGI, with core expertise in technical advisory on complex transactions, debt/equity financing, M&A, auditing, and IPO readiness.



Brian Thompson
Chief Technology Officer

Founder of Pivcon Inc., with a background as a solutions engineer and architect with 30+ years of experience specializing in AI systems, scalable infrastructure, and enterprise software. Delivered 400+ solutions across various industries, including healthcare, across America



**Nikul Panchal,
RPh, BCNP**
Chief Pharmacy Officer

Former Head of Operations at Tollo Health, with prior roles as VP of Pharmacy Operations at TRxADE Health, Inc., Owner of Community Specialty Pharmacy, and Radio Pharmacy Manager for GE Healthcare Diagnostics.

Why Now?

The Window to Enter the Intelligent Healthcare Delivery Era

- ✓ A signed letter of intent is in place to consolidate all aspects of healthcare under one banner
- ✓ Nasdaq-listed DataMeds AI (MEDS, formerly WGRX) provides an established public equity vehicle
- ✓ \$6.5M newly-invested
- ✓ FAA regulatory framework for drone delivery is rapidly advancing — first-mover advantage is time-sensitive
- ✓ IBM partnership expansion as part of DataVault AI milestone provides enterprise-scale distribution
- ✓ NFL Alumni Health partnership — Fox Business/Emmitt Smith & HOF Enshrinement Week exposure

DataMeds AI (MEDS) — Building Healthcare's Last-Mile Future

Important Disclosures

This presentation has been prepared by DataMeds AI, Inc. (formerly Wellgistics Health, Inc.; NASDAQ: MEDS, formerly WGRX) and is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to purchase any securities.

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied.

The \$4 billion post-acquisition value referenced herein is an expectation of the parties subject to delivery of a fairness opinion by a mutually agreed-upon third party. This does not represent a guaranteed valuation.

The Term Sheet signed May 19, 2026 and amended on July 29, 2026, is subject to completion of due diligence, negotiation and execution of definitive agreements, shareholder approval, Nasdaq listing maintenance, and all other customary closing conditions. The proposed transaction involving Tollo Health, LLC is currently structured as a non-binding letter of intent; there can be no assurance that a definitive agreement will be reached on the anticipated terms, or at all.

Securities to be issued in the transaction will not be registered under the Securities Act of 1933. Investment in any securities described herein involves significant risk. Investors should conduct their own due diligence and consult with their financial, legal, and tax advisors.

This presentation may not be reproduced, redistributed, or used for any purpose without the written consent of DataMeds AI, Inc.